Biotech Fund Flanders
VC Fund
Antwerp, Belgium
Biotech Fund Flanders is a VC fund in Antwerp focused on Biotechnology and Pharmaceutical. The Fund was established in 1994 to provide investment support for emerging biotech companies in the region and over its first 10 years invested some 36.3 million euro in businesses that ranged from Plant Genetic Systems, Innogenetics, Devgen and, most recently, Galapagos, a new listing on the stock exchange.Biotech Fund Flanders, whoseportfolio and investment policy were managed by the Governmentâ€:tm:s investment agency GIMV, was due to close investment activities after 10 years and perform only follow-up tasks until 2009. The Minister for the Economy, Fientje Moerman, has announced, however, that it will continue to operate until 2010.No additional money will be made available – the Fund has some 12 million euro of its own resources from sales of previously held shares and is to recycle this and other returns. Its current portfolio includes investments valued at 19.7 million euro in six companies
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Biotech Fund Flanders invests in
Stages Biotech Fund Flanders invests in
Countries Biotech Fund Flanders invests in
Investment Focus
Industry
- Biotechnology 5 (71%)
- Pharmaceutical 3 (43%)
- Biopharma 2 (29%)
- Medical 1 (14%)
- Veterinary 1 (14%)
Stage
- Series B 3 (43%)
- Series C 2 (29%)
- Series D 1 (14%)
- Private Equity 1 (14%)
Country
- Belgium 4 (57%)
- Togo 1 (14%)
- France 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline. The livestock industry is a 100+ billion-euro industry. Viraldiseases cost producers billions every year in losses and threaten the world supply of animal protein.The strategy of ViroVet is to provide novel solutions to be used alone or in combination with vaccines and biosecurity measures in order to provide livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.It is clear that with the growing world population there is an increased demand for more protein-rich diets. With the increasing density of the livestock industry, the intensifying global trade and climate changes, there is an ever increased risk for the global spread of viral diseases, severely damaging livestock industry.ViroVet has already enlisted the support of a number of key opinion leaders (KOLs) in livestock medicine confirming the extensive market for antiviral drugs and novel vaccines addressing the challenges of spreading viral diseases. KOLs feel that ViroVet’s products have the potential to reduce the use of antibiotics and revolutionize the livestock industry worldwide. | $6.6M / Series B / May 28, 2020 | ||
| Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base ofinvestors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium. | Series C / Jan 20, 2012 | ||
| ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium. | $14.8M / Private Equity / Feb 11, 2009 | ||
| Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA.Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improvedbiodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP). | $12.8M / Series D / Jul 03, 2007 | ||
| Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipelineand five Nanobodies in clinical development. | $50M / Series C / Aug 23, 2006 | ||
| Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipelineand five Nanobodies in clinical development. | $30M / Series B / Apr 06, 2004 | ||
Devgen
|
Devgen is an tech company willing to change the work and make impact on people lives. | $25.2M / Series B / Oct 01, 1999 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Biotech Fund Flanders invest in?
Biotech Fund Flanders invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Biotech Fund Flanders last invest?
The most recent investment recorded for Biotech Fund Flanders closed in May 2020. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
